Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1641-1660 of 2,120 trials

CAR T Cell Therapy for Acute Leukemia in Young Patients

We are studying a new treatment using donor-derived CAR T cells for children and young adults with recurrent acute leukemia. The trial aims to assess the safety and effectiveness of this therapy after previous stem cell transplantation.

Recurrent Acute Lymphocytic Leukaemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Preventing Relapses in Minimal Change Nephrotic Syndrome with Rituximab

We are studying whether Rituximab can help adults with Minimal Change Nephrotic Syndrome stay in remission after their first episode. This trial looks at the effectiveness and safety of the treatment over time.

Minimal Change Nephrotic Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNephrology

Oropharyngeal Cancer: Comparing Treatment Options

We are studying different treatment regimens for patients with intermediate and high-risk oropharyngeal cancer to see if they improve survival and quality of life. This trial also aims to evaluate side effects and the cost-effectiveness of these treatments.

Oropharyngeal Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

Polycythemia Vera>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Pediatric Hepatic Tumor Trial: Evaluating Treatments for Hepatoblastoma and Hepatocellular Carcinoma

We are studying different treatment approaches for children with liver tumors to see which may improve outcomes and reduce side effects. This trial also aims to collect samples for future research on these cancers.

Liver Cancer (Hepatoblastoma and Hepatocellular Carcinoma)≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHepatologyOncology

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin Study for Children

We are testing a new treatment combining gemtuzumab ozogamicin with standard chemotherapy for children with acute myeloid leukemia. The study aims to find the best dose and compare its effectiveness with current therapies.

Acute Myeloid LeukaemiaConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

Acute Myeloid Leukemia: Venetoclax vs. Intensive Chemotherapy

We are studying whether venetoclax with low-dose cytarabine can improve outcomes for patients with favorable risk acute myeloid leukemia compared to intensive chemotherapy. This trial will help us understand the best treatment options for this condition.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cancer Imaging: New Non-Invasive Technique

We are exploring a new imaging method that combines two techniques to study how cancer cells and healthy tissues use energy. This may help improve cancer diagnosis and treatment strategies.

Pancreatic Neuroendocrine TumorNeuroendocrine CarcinomaSoft Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementAllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Breast Cancer Treatment: Fulvestrant with Palbociclib

We are studying whether combining fulvestrant with palbociclib helps postmenopausal women with hormone receptor-positive metastatic breast cancer live longer without disease progression compared to fulvestrant alone. This trial is for women who have completed at least five years of hormonal therapy and remained disease-free for over a year, or who have newly diagnosed metastatic disease.

Metastatic Breast Cancer1-2 yearsEfficacy phase (II)Standard MedicinesOncology

HIV-1 Infection: ART with Long-Acting Antibodies

We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.

HIV-1 Infection>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Immunotherapy for Cutaneous Squamous Cell Carcinoma

We are studying whether immunotherapy can help patients with skin cancer achieve remission without surgery or radiation. This trial aims to assess the treatment's effectiveness and safety over time.

Skin Cancer (Cutaneous Squamous Cell Carcinoma)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Neuroendocrine Neoplasms: Advanced PET/CT Imaging Study

We are exploring how combined PET/CT scans can help predict survival outcomes for patients with neuroendocrine neoplasms. This study may also identify who is eligible for targeted therapies based on imaging results.

Neuroendocrine Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyOncology

Immune Thrombocytopenia: Rituximab with Belimumab

We are studying whether adding belimumab to rituximab helps adults with persistent immune thrombocytopenia. This trial will compare the effects of the combination treatment to rituximab alone.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesHematology

Recurrent Brain Tumors in Children: Ultrasound Blood-Brain Barrier Study

We are evaluating a new ultrasound device to safely open the blood-brain barrier before chemotherapy in children with recurrent brain tumors. This study aims to see how well this method works and its effects on tumor progression.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesNeurologyOncologyPediatrics

Early Breast Cancer: Trastuzumab-Deruxtecan vs. Standard Care

We are studying a new treatment for early breast cancer patients who have had a molecular relapse. The trial aims to see if this new therapy clears cancer markers more effectively than standard treatments.

HER2-positive Breast CancerBreast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: S 95005 with Bevacizumab

We are studying a new treatment combination for patients with metastatic colorectal cancer who cannot receive intensive therapy. The goal is to see if it helps patients live longer without disease progression compared to standard treatment.

Metastatic Colorectal Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Liver Transplant: QEL-001 Treatment Study

We are testing a new CAR T cell therapy for patients who received an HLA-A2 mismatched liver transplant. The goal is to evaluate its safety and how well it works in this specific group.

Liver Transplant Rejection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

High-Risk Breast Cancer: Personalized Chemotherapy Study

We are investigating a new chemotherapy treatment for patients with high-risk, HER2-negative breast cancer to see if it improves survival rates compared to standard therapies. This trial is for individuals with specific genetic profiles, including those without known BRCA mutations.

Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Intensive Care: INCEPT Trial

We are studying different treatments for adults admitted to the intensive care unit to see how they affect recovery. This trial aims to improve care by understanding the best practices among clinicians.

Intensive Care>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious DiseasesInternal MedicineNeurologyPulmonology

Glioblastoma Multiforme: Long-Term Safety of Temferon

We are monitoring the long-term safety and effects of Temferon in patients who have been treated for glioblastoma multiforme. This study aims to understand any potential side effects and how the disease may progress.

Glioblastoma MultiformeSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurologyOncology